These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31628561)

  • 1. Variation in receipt of therapy and survival with provider volume for medical oncology in non-curative esophago-gastric cancer: a population-based analysis.
    Hallet J; Davis LE; Mahar AL; Liu Y; Zuk V; Gupta V; Earle CC; Coburn NG
    Gastric Cancer; 2020 Mar; 23(2):300-309. PubMed ID: 31628561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits of High-Volume Medical Oncology Care for Noncurable Pancreatic Adenocarcinoma: A Population-Based Analysis.
    Hallet J; Davis L; Mahar A; Mavros M; Beyfuss K; Liu Y; Law CHL; Earle C; Coburn N
    J Natl Compr Canc Netw; 2020 Mar; 18(3):297-303. PubMed ID: 32135510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic impacts of care by high-volume providers for non-curative esophagogastric cancer: a population-based analysis.
    Hallet J; Look Hong NJ; Zuk V; Davis LE; Gupta V; Earle CC; Mittmann N; Coburn NG
    Gastric Cancer; 2020 May; 23(3):373-381. PubMed ID: 31834527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Treatment at High-Volume Facilities and Improved Overall Survival in Soft Tissue Sarcomas.
    Venigalla S; Nead KT; Sebro R; Guttmann DM; Sharma S; Simone CB; Levin WP; Wilson RJ; Weber KL; Shabason JE
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):1004-1015. PubMed ID: 29485042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma.
    Huntington SF; Hoag JR; Zhu W; Wang R; Zeidan AM; Giri S; Podoltsev NA; Gore SD; Ma X; Gross CP; Davidoff AJ
    Cancer; 2018 Nov; 124(21):4211-4220. PubMed ID: 30216436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Geographic impact on access to care and survival for non-curative esophagogastric cancer: a population-based study.
    Yee EK; Coburn NG; Zuk V; Davis LE; Mahar AL; Liu Y; Gupta V; Darling G; Hallet J
    Gastric Cancer; 2021 Jul; 24(4):790-799. PubMed ID: 33550518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced oesophagogastric cancer.
    Sylvie L; Silvia S; Salah-Eddin AB; Markus F; Florian L; Peter TP; Bernhard H; Martin A; Alexander N
    Eur J Cancer; 2015 Sep; 51(14):1918-26. PubMed ID: 26216588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of esophageal and gastric cancer patients with adjuvant and palliative chemotherapy-a retrospective analysis of a register-based patient cohort.
    Ekheden I; Ebrahim F; Ólafsdóttir H; Raaschou P; Wettermark B; Henriksson R; Ye W
    Eur J Clin Pharmacol; 2020 Jul; 76(7):1029-1041. PubMed ID: 32372150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer.
    Aviki EM; Lavery JA; Roche KL; Cowan R; Dessources K; Basaran D; Green AK; Aghajanian CA; O'Cearbhaill R; Jewell EL; Leitao MM; Gardner GJ; Abu-Rustum NR; Sabbatini P; Bach PB
    Gynecol Oncol; 2020 Nov; 159(2):418-425. PubMed ID: 32814642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hospital volume and beyond first-line palliative systemic treatment in metastatic oesophagogastric adenocarcinoma: A population-based study.
    Dijksterhuis WPM; Verhoeven RHA; Pape M; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; Lemmens VEPP; van Oijen MGH; van Laarhoven HWM
    Eur J Cancer; 2020 Nov; 139():107-118. PubMed ID: 32980749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03).
    Athauda A; Nankivell M; Langley RE; Alderson D; Allum W; Grabsch HI; Starling N; Chau I; Cunningham D
    Eur J Cancer; 2020 Sep; 137():45-56. PubMed ID: 32745964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices.
    Paulson AS; Hess LM; Liepa AM; Cui ZL; Aguilar KM; Clark J; Schelman W
    Gastric Cancer; 2018 Sep; 21(5):831-844. PubMed ID: 29397460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in Advanced Gastric Cancer.
    Vasista A; Stockler M; Martin A; Pavlakis N; Sjoquist K; Goldstein D; Gill S; Jain V; Liu G; Kannourakis G; Kim YH; Nott L; Snow S; Burge M; Harris D; Jonker D; Chua YJ; Epstein R; Bonaventura A; Kiely B
    Oncologist; 2019 Nov; 24(11):e1102-e1107. PubMed ID: 30936377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective cohort study of patients with stomach and liver cancers: the impact of comorbidity and ethnicity on cancer care and outcomes.
    Sarfati D; Gurney J; Stanley J; Koea J
    BMC Cancer; 2014 Nov; 14():821. PubMed ID: 25380581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.
    Greally M; Chou JF; Chatila WK; Margolis M; Capanu M; Hechtman JF; Tuvy Y; Kundra R; Daian F; Ladanyi M; Kelsen DP; Ilson DH; Berger MF; Tang LH; Solit DB; Diaz LA; Schultz N; Janjigian YY; Ku GY
    Clin Cancer Res; 2019 Oct; 25(20):6160-6169. PubMed ID: 31337644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study.
    Dijksterhuis WPM; Verhoeven RHA; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
    Int J Cancer; 2020 Apr; 146(7):1889-1901. PubMed ID: 31340065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
    Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
    Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrectomy case volume and textbook outcome: an analysis of the Population Registry of Esophageal and Stomach Tumours of Ontario (PRESTO).
    Levy J; Gupta V; Amirazodi E; Allen-Ayodabo C; Jivraj N; Jeong Y; Davis LE; Mahar AL; De Mestral C; Saarela O; Coburn N;
    Gastric Cancer; 2020 May; 23(3):391-402. PubMed ID: 31686260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
    Sudarshan M; Alcindor T; Ades S; Aloraini A; van Huyse M; Asselah J; David M; Frechette D; Brisson S; Thirlwell M; Ferri L
    Ann Surg Oncol; 2015 Jan; 22(1):324-30. PubMed ID: 25023544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Academic Facility Type and Case Volume on Survival in Patients Undergoing Curative Radiation Therapy for Muscle-Invasive Bladder Cancer.
    Bajaj A; Martin B; Bhasin R; Hentz C; Block AM; Harkenrider MM; Solanki AA
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):851-857. PubMed ID: 29485062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.